Texas House Bill HB4422

Texas 2025 - 89th Regular

• Filed: 3/11/25

Caption

Relating to discriminatory practices by a health benefit plan issuer, pharmacy benefit manager, and third-party payor with respect to certain entities participating in a federal drug discount program.

Impact

If enacted, HB4422 will significantly affect the Insurance Code by adding a new subchapter dedicated to prohibiting discrimination based on 340B participation. The implications of this bill may extend to various health system stakeholders, as it will prohibit actions that could hinder the ability of covered entities to provide access to affordable medications. This legislative move seeks to uphold fairness in drug reimbursement mechanisms, ultimately aiming to benefit vulnerable populations served by these entities.

Summary

House Bill 4422 addresses discriminatory practices by health benefit plan issuers, pharmacy benefit managers, and third-party payors in relation to entities participating in the federal 340B drug discount program. Specifically, the bill aims to create a legal framework to ensure that covered entities in the 340B program are not subjected to unfair treatment compared to non-covered entities. This includes provisions to prevent discriminatory pricing practices that might disadvantage these entities in the procurement of prescription drugs.

Contention

Key points of contention surrounding HB4422 may arise from varying perspectives among health benefit plan issuers and pharmacy benefit managers. While proponents argue that the bill protects entities in the 340B program and enhances patient access to necessary medications, opponents may voice concerns about the operational and financial burdens that could result from increased regulatory oversight. The discourse may focus on how this balance of interests is handled and whether it appropriately addresses the potential impact on overall healthcare costs.